Search Videos by Topic or Participant
Browse by Series:

Gene Expression Profiling in Multiple Myeloma

Panelists: James R. Berenson, MD, IMBCR; Sundar Jagannath, MD, Tisch Cancer Institute; Shaji Kumar, MD, Mayo; Sagar Lonial, MD, Emory; A. Kei
Published: Thursday, Jan 22, 2015
For High-Definition, Click
Diagnostic tests, such as fluorescence in situ hybridization (FISH) and cytogenetics, help to identify individuals who have moved from smoldering myeloma to active multiple myeloma. According to Sundar Jagannath, MD, in this era of genomic medicine, gene expression profiling may play a role in defining myeloma and assessing risk of the disease, as it provides more information than FISH and cytogenetics.

Currently, gene expression profiling is only used prognostically and does not help guide management of the high-risk patient, notes Jagannath. Jeffrey A. Zonder, MD, and Sagar Lonial, MD, agree that although gene expression profiling offers more information, it is not ready to be used in standard practice.

James R. Berenson, MD, explains that he and colleagues have identified a new solubilized receptor, known as B-cell maturation antigen (BCMA), which has been shown to be highly prognostic; it also may be used to monitor multiple myeloma in the future.
Slider Left
Slider Right
For High-Definition, Click
Diagnostic tests, such as fluorescence in situ hybridization (FISH) and cytogenetics, help to identify individuals who have moved from smoldering myeloma to active multiple myeloma. According to Sundar Jagannath, MD, in this era of genomic medicine, gene expression profiling may play a role in defining myeloma and assessing risk of the disease, as it provides more information than FISH and cytogenetics.

Currently, gene expression profiling is only used prognostically and does not help guide management of the high-risk patient, notes Jagannath. Jeffrey A. Zonder, MD, and Sagar Lonial, MD, agree that although gene expression profiling offers more information, it is not ready to be used in standard practice.

James R. Berenson, MD, explains that he and colleagues have identified a new solubilized receptor, known as B-cell maturation antigen (BCMA), which has been shown to be highly prognostic; it also may be used to monitor multiple myeloma in the future.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x